Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TRAVASOL 8.5% IN PLASTIC CONTAINER vs TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 5% IN PLASTIC CONTAINER
Head-to-head clinical comparison of therapeutic indices and safety profiles.
TRAVASOL 8.5% is a crystalline amino acid solution that provides essential and non-essential amino acids for protein synthesis, tissue repair, and maintenance of nitrogen balance in patients unable to tolerate enteral nutrition.
Amino acids serve as substrates for protein synthesis and intermediary metabolism; dextrose provides caloric replacement; electrolytes maintain acid-base and electrolyte balance.
Total parenteral nutrition in patients with inadequate oral or enteral intake,Protein calorie malnutrition,Catabolic states (e.g., burns, major surgery, trauma)
Source of protein, calories, and electrolytes for parenteral nutrition in patients unable to tolerate oral/enteral intake
Intravenous administration as total parenteral nutrition: typical adult dose is 8.5% amino acid solution at 0.8-1.5 g protein/kg/day, infused continuously or cyclically.
Intravenous infusion; typical adult dose is 500 m L to 1000 m L per day administered as a continuous or intermittent infusion, providing 4.25% amino acids and 5% dextrose. Rate adjusted based on metabolic needs and tolerance.
Not applicable; constituent amino acids have individual half-lives (e.g., 0.5–2 hours for most L-amino acids) but overall elimination follows zero-order kinetics during continuous infusion. Clinically, infusion rate determines steady-state concentrations.
Not applicable as a composite; amino acids have varying half-lives (minutes). Dextrose: glucose half-life ~1.5-2.5 hours in healthy individuals. Clinical context: continuous infusion maintains steady state.
GFR 30-59 m L/min: reduce to 0.5-0.8 g protein/kg/day; GFR <30 m L/min: 0.4-0.5 g/kg/day; monitor BUN and electrolytes.
For GFR <50 m L/min: use with caution; may require reduction in volume and amino acid load to avoid fluid overload and accumulation of nitrogenous waste. For GFR <15 m L/min: avoid use or use only under strict monitoring with dose reduction of 50% or more.
Not for use in patients with severe hepatic failure, severe uremia, or inborn errors of amino acid metabolism. Risk of hyperammonemia and metabolic acidosis.
Amino acid solutions like TRAVASOL 8.5% are essential for maternal nutrition in pregnancy; however, there are no well-controlled studies in pregnant women. Animal reproduction studies have not been conducted. Use during pregnancy only if clearly needed. First trimester: potential risks are not established; avoid unless maternal benefit outweighs unknown fetal risk. Second and third trimesters: may be used cautiously for nutritional support, with monitoring for electrolyte imbalances and fluid overload in the fetus.
Parenteral amino acids and dextrose are standard components of total parenteral nutrition (TPN). No teratogenic effects attributable to these components in standard doses have been reported. However, any underlying maternal condition requiring TPN may pose fetal risks. Use only if clearly needed in pregnancy.
TRAVASOL 8.5% is a crystalline amino acid solution used for parenteral nutrition. It contains 8.5% amino acids and provides 85 g protein/L. It is hypertonic (approx. 880 m Osm/L) and must be administered via a central line to avoid thrombophlebitis. Shake container vigorously before use; do not use if cloudy or precipitate present. Do not add medications directly to the plastic container without checking compatibility. Protect from light; do not freeze. Use dedicated IV line without simultaneous blood products due to risk of agglomeration.
This formulation is a 4.25% amino acid solution with 5% dextrose and electrolytes, designed for peripheral parenteral nutrition (PPN). It is sulfite-free, reducing risk of allergic reactions in sulfite-sensitive patients. Monitor serum electrolytes, glucose, and nitrogen balance daily. Do not administer if solution is discolored or contains particulates. Use within 24 hours of spiking the container. Incompatible with lipid emulsions in the same container.
No interactions on record
No interactions on record
TRAVASOL 8.5% IN PLASTIC CONTAINER and TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 5% IN PLASTIC CONTAINER are distinct pharmacological agents. TRAVASOL 8.5% IN PLASTIC CONTAINER belongs to the Amino Acid Solution class and is primarily used for Total parenteral nutrition in patients with inadequate oral or enteral intakeProtein calorie malnutritionCatabolic states (e.g., burns, major surgery, trauma). TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 5% IN PLASTIC CONTAINER belongs to the Amino Acid Solution class and is primarily used for Source of protein, calories, and electrolytes for parenteral nutrition in patients unable to tolerate oral/enteral intake. Their specific mechanisms of action, pharmacokinetic characteristics, and side effects differ.
The maternal-fetal safety profiles of these drugs differ. TRAVASOL 8.5% IN PLASTIC CONTAINER carries a safety status of Category C, whereas TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 5% IN PLASTIC CONTAINER safety is classified as Category C. Consult a board-certified physician or healthcare specialist to establish an accurate, individualized pregnancy risk assessment before starting either therapy.
Amino acids are metabolized via deamination, transamination, and oxidative pathways primarily in the liver. Nitrogen is incorporated into urea via the urea cycle.
Amino acids are metabolized via deamination, transamination, and oxidation; dextrose undergoes glycolysis and oxidation; electrolytes are excreted renally.
Renal elimination of nitrogenous waste products (urea, ammonia) derived from amino acid metabolism; biliary/fecal excretion negligible. In healthy adults, >90% of infused amino nitrogen is ultimately excreted as urea in urine.
Amino acids: renal elimination of unmodified amino acids is minimal (<5%); most nitrogen is excreted as urea via kidneys. Dextrose: fully metabolized, negligible renal excretion of intact glucose. Electrolytes: renally excreted.
Minimal (<10%) for individual amino acids; binding to albumin or other plasma proteins is negligible. Transport is primarily via specific carrier-mediated processes.
Amino acids: negligible (<5%). Dextrose: none. Electrolytes: variable (e.g., calcium ~45% bound to albumin).
Approximately 0.3–0.5 L/kg for total amino acids, reflecting distribution into total body water and intracellular compartments. Higher distribution for branched-chain amino acids (leucine, isoleucine, valine) into muscle.
Not a single Vd; amino acids distribute widely (0.5-2 L/kg). Dextrose Vd ~0.2 L/kg (total body water). Electrolytes: Vd corresponds to distribution spaces (e.g., sodium ≈0.25 L/kg).
Intravenous: 100% (complete). Not administered orally; if taken orally, amino acids are absorbed with bioavailability >90% but first-pass metabolism reduces systemic availability of some (e.g., glutamine, alanine).
Intravenous: 100%.
Child-Pugh Class A: no adjustment; Class B: reduce to 0.6-0.8 g protein/kg/day; Class C: 0.4-0.6 g/kg/day; avoid in hepatic encephalopathy.
Child-Pugh Class A: no adjustment. Class B: reduce dose by 25-50% to avoid precipitating hepatic encephalopathy. Class C: avoid use or use minimal amounts with close monitoring.
Weight-based: 1.0-2.5 g protein/kg/day intravenously, adjusted for age and clinical status; neonates: 1.5-3.0 g/kg/day.
Weight-based: initial dose 0.5-1.0 g amino acids/kg/day (equivalent to 12-24 m L/kg/day of this solution) via intravenous infusion; titrate up to 2-3 g/kg/day based on tolerance and metabolic needs.
Start at lower end of adult range (0.8-1.0 g/kg/day) and titrate based on renal function and metabolic tolerance; monitor fluid and electrolyte balance closely.
Elderly patients may have reduced renal and hepatic function; begin at lower end of dosing range (e.g., 250-500 m L/day) and monitor for fluid overload, electrolyte disturbances, and azotemia; adjust based on clinical response and laboratory values.
Not for use in patients with severe lactic acidosis, hyperglycemic hyperosmolar state, or severe metabolic alkalosis. Risk of infections, sepsis, and metabolic complications from central line administration.
There are no direct food interactions as this is an intravenous solution. However, oral food intake is usually restricted or absent during parenteral nutrition therapy. Monitor for refeeding syndrome in severely malnourished patients.
None known, as this is for parenteral use. However, monitor glucose levels closely due to dextrose content.
TRAVASOL 8.5% is a sterile, hypertonic amino acid solution for intravenous infusion. It is unknown whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when TRAVASOL 8.5% is administered to a nursing woman. The molecular weight of amino acids (< 200 Da) suggests potential for transfer into breast milk, but clinical significance is low due to endogenous presence. M/P ratio: not established.
No specific M/P ratio data available. Parenteral amino acids and dextrose are considered compatible with breastfeeding when administered as part of TPN, as they are normal blood constituents. However, caution should be exercised due to lack of specific safety data in lactating women.
No specific dose adjustments are recommended during pregnancy based on pharmacokinetic changes. However, pregnancy increases plasma volume and renal blood flow, potentially altering amino acid clearance. Dose should be individualized based on maternal nutritional status, clinical response, and laboratory monitoring. Avoid overhydration and hyperglycemia. Use with caution in preeclampsia or gestational diabetes.
No specific dose adjustments are recommended for this drug in pregnancy. However, pregnancy may alter metabolic demands; ensure adequate caloric and amino acid intake. Monitor for hyperglycemia and adjust dextrose concentration or insulin as needed.
This medication is given through a vein to provide protein calories when you cannot eat normally.,Your healthcare provider will monitor your blood sugar, kidney, and liver function regularly.,Tell your doctor if you experience fever, chills, flushing, or injection site pain.,Do not stop or adjust the infusion rate without consulting your healthcare team.,If you have diabetes, your blood glucose may rise; follow your management plan.
This solution provides nutrition through a vein and is not for oral consumption.,Report any signs of infection at the IV site (redness, swelling, pain) or difficulty breathing immediately.,You may need regular blood tests to monitor your sugar and electrolyte levels.,Do not stop the infusion or adjust the rate on your own.,Notify your healthcare provider if you experience nausea, headache, or swelling in your legs.